[肺鳞状细胞癌驱动癌基因的研究进展]
[Advances on driver oncogenes of squamous cell lung cancer].
作者信息
Hong Wei, Zhang Yiping
机构信息
Zhejiang Cancer Hospital, Zhejiang Key Laboratory of the Diagnosis & Treatment Technology on Thoracic Oncology, Hangzhou 310022, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2014 May;17(5):433-6. doi: 10.3779/j.issn.1009-3419.2014.05.13.
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. Next to adenocarcinoma, squamous cell carcinoma (SCC) of the lung is the most frequent histologic subtype in non-small cell lung cancer. Several molecular alterations have been defined as "driver oncogenes" responsible for both the initiation and maintenance of the malignancy. The squamous cell carcinoma of the lung has recently shown peculiar molecular characteristics which relate with both carcinogenesis and response to targeted drugs. So far, about 40% of lung squamous cell carcinoma has been found harbouring driver oncogenes, in which fibroblast growth factor receptor 1 (FGFR1) plays important roles. In this review, we will report the mainly advances on some latest driver mutations of squamous cell lung cancer.
摘要
肺癌是全球癌症相关死亡的主要原因。在非小细胞肺癌中，肺鳞状细胞癌（SCC）是仅次于腺癌的最常见组织学亚型。几种分子改变已被定义为负责恶性肿瘤起始和维持的“驱动癌基因”。肺鳞状细胞癌最近显示出与致癌作用和靶向药物反应相关的独特分子特征。到目前为止，已发现约40%的肺鳞状细胞癌携带驱动癌基因，其中成纤维细胞生长因子受体1（FGFR1）发挥重要作用。在本综述中，我们将报告肺鳞状细胞癌一些最新驱动突变的主要进展。
相似文献
1
[Advances on driver oncogenes of squamous cell lung cancer].[肺鳞状细胞癌驱动癌基因的研究进展]
Zhongguo Fei Ai Za Zhi. 2014 May;17(5):433-6. doi: 10.3779/j.issn.1009-3419.2014.05.13.
2
[Advances on driver oncogenes of lung adenocarcinoma].[肺腺癌驱动癌基因的研究进展]
Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):91-6. doi: 10.3779/j.issn.1009-3419.2013.02.06.
3
[Advances on driver oncogenes of non-small cell lung cancer].[非小细胞肺癌驱动癌基因的研究进展]
Zhongguo Fei Ai Za Zhi. 2015 Jan;18(1):42-7. doi: 10.3779/j.issn.1009-3419.2015.01.07.
4
FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.肺鳞状细胞癌中 FGFR1 基因扩增：女性和晚期癌症患者潜在的有利预后标志物。
Virchows Arch. 2018 May;472(5):759-769. doi: 10.1007/s00428-017-2282-0. Epub 2017 Dec 21.
5
Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.成纤维细胞生长因子受体1、成纤维细胞生长因子2、磷脂酰肌醇3磷酸激酶在肺鳞状细胞癌早期和晚期的表达及其临床和预后意义
Int J Clin Exp Pathol. 2015 Sep 1;8(9):9760-71. eCollection 2015.
6
FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.FGFR1/3 酪氨酸激酶融合定义了非小细胞肺癌的一个独特分子亚型。
Clin Cancer Res. 2014 Aug 1;20(15):4107-14. doi: 10.1158/1078-0432.CCR-14-0284. Epub 2014 May 21.
7
FGFR1 amplification in squamous cell carcinoma of the lung.肺鳞状细胞癌中 FGFR1 扩增。
J Thorac Oncol. 2012 Dec;7(12):1775-1780. doi: 10.1097/JTO.0b013e31826aed28.
8
Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing.采用下一代测序技术分析肺鳞癌 DDR2 基因的突变特征。
Clin Lung Cancer. 2018 Mar;19(2):163-169.e4. doi: 10.1016/j.cllc.2017.10.006. Epub 2017 Oct 19.
9
Increased FGFR1 copy number in lung squamous cell carcinomas.肺鳞状细胞癌中 FGFR1 拷贝数增加。
Mol Med Rep. 2012 Mar;5(3):725-8. doi: 10.3892/mmr.2011.715. Epub 2011 Dec 15.
10
Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer.成纤维细胞生长因子受体 1 基因扩增和蛋白表达在人肺癌中的研究。
Cancer Med. 2020 May;9(10):3574-3583. doi: 10.1002/cam4.2994. Epub 2020 Mar 24.
引用本文的文献
1
Elucidating the clonal relationship of esophageal second primary tumors in patients with laryngeal squamous cell carcinoma.阐明喉鳞状细胞癌患者食管第二原发性肿瘤的克隆关系。
Infect Agent Cancer. 2023 Nov 28;18(1):75. doi: 10.1186/s13027-023-00558-z.
本文引用的文献
1
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.厄洛替尼对比吉非替尼用于经治的晚期非小细胞肺癌（ICOGEN）：一项随机、双盲、III 期非劣效性试验
Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13.
2
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
3
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.替沃扎尼（Tivantinib，ARQ197）显示出细胞毒性活性，而这种活性与其结合 MET 的能力无关。
Clin Cancer Res. 2013 May 1;19(9):2381-92. doi: 10.1158/1078-0432.CCR-12-3459. Epub 2013 Mar 26.
4
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.成纤维细胞生长因子受体 1 基因扩增与可切除的鳞状细胞肺癌患者的不良预后和吸烟剂量有关。
J Clin Oncol. 2013 Feb 20;31(6):731-7. doi: 10.1200/JCO.2012.43.8622. Epub 2012 Nov 26.
5
FGFR1 amplification in squamous cell carcinoma of the lung.肺鳞状细胞癌中 FGFR1 扩增。
J Thorac Oncol. 2012 Dec;7(12):1775-1780. doi: 10.1097/JTO.0b013e31826aed28.
6
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer.MetLung 试验的治疗原理研究设计：一项 Onartuzumab（MetMAb）联合厄洛替尼与厄洛替尼单药治疗标准化疗后 IIIB 或 IV 期 MET 阳性非小细胞肺癌患者的随机、双盲 III 期研究。
Clin Lung Cancer. 2012 Nov;13(6):500-4. doi: 10.1016/j.cllc.2012.05.009.
7
Comprehensive genomic characterization of squamous cell lung cancers.全面基因组特征分析鳞状细胞肺癌
Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9.
8
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.吉非替尼对比培美曲塞作为含铂化疗后进展的非小细胞肺癌患者的二线治疗（KCSG-LU08-01）：一项开放标签、III 期临床试验。
Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6.
9
Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.肺鳞状细胞癌：分子亚型与治疗机会。
Clin Cancer Res. 2012 May 1;18(9):2443-51. doi: 10.1158/1078-0432.CCR-11-2370. Epub 2012 Mar 8.
10
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.DDR2 激酶基因突变鉴定出鳞状细胞肺癌的一个新的治疗靶点。
Cancer Discov. 2011 Jun;1(1):78-89. doi: 10.1158/2159-8274.CD-11-0005.
Zotero 插件